Insmed INSM Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Sarepta Therapeutics, Inc.SRPT

$11.2M-15.6%

Solid Biosciences Inc.SLDB

$2.23M+15.0%

Regeneron PharmaceuticalsREGN

$37.8M+24.8%

ArriVent BioPharma, Inc.AVBP

$99K-28.3%

Theravance BiopharmaTBPH

$10.8M-0.9%

Upstream Bio, Inc.UPB

$728K+2.2%

FAQ

What is Insmed's operating lease liabilities (current)?

Insmed (INSM) reported operating lease liabilities (current) of $6.27M in Q2 2026.

How has Insmed's operating lease liabilities (current) changed year-over-year?

Insmed's operating lease liabilities (current) increased by 78.4% year-over-year, from $3.51M to $6.27M.

What is the long-term trend for Insmed's operating lease liabilities (current)?

Over 5 years (2020 to 2025), Insmed's operating lease liabilities (current) has grown at a -3.8% compound annual growth rate (CAGR), from $11.48M to $9.47M.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.